RxDoctor Payments Data

David Hartzell, MD

Ophthalmology · Carlisle, PANPI 1912001389

Payments from drug & device makers

$6,252in general payments, 2019–2025

Across 117 payments — averaging $53.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec USA, Inc.$3K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
  • Alcon$474
  • AbbVie$447
  • Bausch & Lomb Americas Inc.$357
  • Novartis$113
  • plus $604 from 12 others

What the payments were for

  • Travel & lodging$3,26852%
  • Food & beverage$2,91947%
  • Gifts$641%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,252 in reported general payments places this provider in the 80th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$431,880
Medicare patients
1,299
Services billed
3,903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost111$62,550
RestasisCyclosporine53$47,921
XiidraLifitegrast28$20,723
CombiganBrimonidine Tartrate/Timolol38$19,961
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol69$15,350
RhopressaNetarsudil Mesylate20$14,126
SimbrinzaBrinzolamide/Brimonidine Tart32$13,830
TyrvayaVarenicline Tartrate17$12,881
Cyclosporine27$12,421
Alphagan PBrimonidine Tartrate19$12,333
Travoprost35$10,611
RocklatanNetarsudil Mesylat/Latanoprost13$8,838
IlevroNepafenac14$8,709
Dorzolamide-TimololDorzolamide/Timolol/Pf29$4,819
Prednisolone Acetate151$4,624

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$447$142,764221 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$45$22,96433 claims
Bausch & Lomb Americas Inc.Xiidra$357$20,72328 claims
AlconSimbrinza$474$13,83032 claims
Oyster Point Pharma, Inc.Tyrvaya$65$12,88117 claims
NovartisIlevro$113$8,70914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Carlisle

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →